AnaptysBio Inc (ANAB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AnaptysBio Inc stock (ANAB) is currently trading at $65.39. AnaptysBio Inc PS ratio (Price-to-Sales) is 7.64. Analyst consensus price target for ANAB is $78.25. WallStSmart rates ANAB as Sell.
- ANAB PE ratio analysis and historical PE chart
- ANAB PS ratio (Price-to-Sales) history and trend
- ANAB intrinsic value — DCF, Graham Number, EPV models
- ANAB stock price prediction 2025 2026 2027 2028 2029 2030
- ANAB fair value vs current price
- ANAB insider transactions and insider buying
- Is ANAB undervalued or overvalued?
- AnaptysBio Inc financial analysis — revenue, earnings, cash flow
- ANAB Piotroski F-Score and Altman Z-Score
- ANAB analyst price target and Smart Rating
AnaptysBio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
AnaptysBio Inc (ANAB) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
AnaptysBio Inc (ANAB) Key Strengths (3)
Keeps $62 of every $100 in revenue after operating costs
Revenue surging 151.10% year-over-year
100.98% of shares held by major funds and institutions
Supporting Valuation Data
AnaptysBio Inc (ANAB) Areas to Watch (5)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 48.3x book value
Premium valuation at 7.6x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
AnaptysBio Inc (ANAB) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, Institutional Own.. Profitability is solid with Operating Margin at 61.80%. Growth metrics are encouraging with Revenue Growth at 151.10%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Book. Some valuation metrics including Price/Sales (7.64), Price/Book (48.26) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -24.50%, Profit Margin at -5.64%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -24.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 151.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ANAB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ANAB's Price-to-Sales ratio of 7.64x trades at a deep discount to its historical average of 81.67x (9th percentile). The current valuation is 98% below its historical high of 425.79x set in Apr 2019, and 50% above its historical low of 5.1x in Feb 2025. Over the past 12 months, the PS ratio has expanded from ~5.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for AnaptysBio Inc (ANAB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
AnaptysBio Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 235M with 151% growth year-over-year. The company is currently unprofitable, posting a -5.6% profit margin.
Key Findings
Revenue growing at 151% YoY, reaching 235M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 98M in free cash flow and 98M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -5.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can AnaptysBio Inc maintain 151%+ revenue growth, or will competition slow it down?
Debt management: total debt of 346M is significantly higher than cash (110M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact AnaptysBio Inc.
Bottom Line
AnaptysBio Inc is a high-conviction growth story with revenue accelerating at 151% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -5.6% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(68 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:25:28 AM
About AnaptysBio Inc(ANAB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.